ArticleScientific reports2017
Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- The multifaceted roles of receptor tyrosine pseudokinases in cellular signalling.Biochemical Society transactions · 2026Review
- Epigenome-wide association study of blood proteome in the Atherosclerosis Risk in Communities study.HGG advances · 2026Article
- Development of a novel anti-erythropoietin-producing hepatocellular receptor B6 monoclonal antibody EbBiochemistry and biophysics reports · 2025Article
- Establishing a prognostic model with immune-related genes and investigating EPHB6 expression pattern in breast cancer.Scientific reports · 2025Article
- Co-clustering of EphB6 and ephrinB1 in trans restrains cancer cell invasion.Communications biology · 2024Article
- Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets.Frontiers in oncology · 2024Review
- Eph receptors and ephrins in cancer progression.Nature reviews. Cancer · 2024Review
- Ephrin-Eph receptor tyrosine kinases for potential therapeutics against hepatic pathologies.Journal of cell communication and signaling · 2023Review
- Eph Receptors in Cancer.Biomedicines · 2023Review
- A computational modeling approach for predicting multicell spheroid patterns based on signaling-induced differential adhesion.PLoS computational biology · 2022Article
- Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region.Analytical cellular pathology (Amsterdam) · 2022Article
- Ephrin Receptors (Ephs) Expression in Thymic Epithelial Tumors: Prognostic Implications and Future Therapeutic Approaches.Diagnostics (Basel, Switzerland) · 2021Article
- The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs.The Biochemical journal · 2021Article
- The EphB6 Receptor: Kinase-Dead but Very Much Alive.International journal of molecular sciences · 2021Review
- Article
- The Role of the Eph Receptor Family in Tumorigenesis.Cancers · 2021Review
- Structure of the EphB6 receptor ectodomain.PloS one · 2021Article
- Identification of long non-coding RNA SCARNA9L as a novel molecular target for colorectal cancer.Oncology letters · 2020Article
- Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑ mesenchymal transition via the AKT/GSK‑3β/Snail signaling pathway.Molecular medicine reports · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 3 countries.
Silvia Mateo-LozanoGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Sarah BazzoccoGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Paulo RodriguesGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Rocco MazzoliniGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Elena AndrettaGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Higinio DopesoGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Yolanda FernándezCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
Edgar Del LlanoGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Josipa BilicGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Lucía Suárez-LópezCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
Irati MacayaGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Fernando Cartón-GarcíaGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Rocio NietoGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Lizbeth M Jimenez-FloresGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Priscila Guimarães de MarcondesGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Yaiza NuñezGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Elsa AfonsoGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Karina CacciDepartment of Pathology, Vall d'Hebron Hospital, Barcelona, Spain (CIBERONC).
Javier Hernández-LosaDepartment of Pathology, Vall d'Hebron Hospital, Barcelona, Spain (CIBERONC).
Stefania LandolfiDepartment of Pathology, Vall d'Hebron Hospital, Barcelona, Spain (CIBERONC).
Ibane AbasoloCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
Santiago Ramón Y CajalDepartment of Pathology, Vall d'Hebron Hospital, Barcelona, Spain (CIBERONC).
John M MariadasonOlivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Simo SchwartzCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
Toshimitsu MatsuiHematology, Department of Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Japan.
Diego ArangoGroup of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBBIM-Nanomedicine · ESUniversitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESCentro de Investigación Biomédica en Red de Cáncer · ESKobe University · JPOlivia Newton-John Cancer Wellness & Research Centre · AU
Funding
Worldwide Cancer Research 13-0245
Abstract
Although deregulation of EPHB signaling has been shown to be an important step in colorectal tumorigenesis, the role of EPHB6 in this process has not been investigated. We found here that manipulation of EPHB6 levels in colon cancer cell lines has no effect on their motility and growth on a solid substrate, soft agar or in a xenograft mouse model. We then used an EphB6 knockout mouse model to show that EphB6 inactivation does not efficiently initiate tumorigenesis in the intestinal tract. In addition, when intestinal tumors are initiated genetically or pharmacologically in EphB6
Indexed as
Biomarkers, TumorAnimalsCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticColorectal NeoplasmsDisease Models, AnimalGene ExpressionHumansImmunohistochemistryMiceMice, KnockoutNeoplasm MetastasisNeoplasm StagingPrognosisBiomarkers, TumorEPHB6 protein, humanReceptors, Eph Family
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.